***Sponsored by Interactive Offers, LLC
HCTI is looking to acquire Teyame.AI, a European company expected to generate $34 million in annual revenue
Healthcare Triangle Subsidiary QuantumNexis Reports $20M in Consumption-Based Revenue Processed on Ezovion Platform, Forecasts $37M Amid Rapid Growth
READ THE INVESTOR PRESENTATION HERE
__________________________________
Hello Everyone,
How about today’s Uranium profile? It went completely parabolic before hitting resistance at the $5 level. The 52 week high is not too far off. It was up over 20% for most of the session.
We have a new profile that we want you to research ahead of Wednesday’s session.
One of the key catalysts is the massive reverse split that took place just a few weeks back on August first.
This puts the float currently under 6 million.
Artificial intelligence is transforming the landscape of modern healthcare — and few companies are embracing that shift as decisively as Healthcare Triangle Inc. (NASDAQ: HCTI).
As the global AI healthcare market accelerates toward nearly $188 billion by 2030, growing at a projected 38.6% CAGR (GrandView Research), the race to fuse data, automation, and intelligence for better patient outcomes is well underway. HCTI isn’t just participating — it’s leading from the front.
With a market capitalization under $20 million, the California-based innovator is executing a focused, fast-moving growth plan: acquiring cutting-edge AI technologies, expanding internationally, and building healthcare systems that turn raw data into actionable insights.
Its pending Teyame. AI acquisition, expected to contribute $34 million in annual revenue and $4.2 million in EBITDA, positions HCTI as a next-generation healthcare powerhouse — one capable of transforming compliance-grade infrastructure into smart, multilingual engagement and real-time analytics.
The company’s QuantumNexis AI platform already integrates data across research, clinical, and administrative silos — linking every part of the healthcare ecosystem under one intelligent, digital network. Alongside recent acquisitions like Niyama Healthcare and Ezovion Solutions, HCTI is assembling a full-stack platform that delivers automation, scalability, and seamless engagement.
Even its financial strategy reflects discipline: a strategically structured 2.8 million warrant inducement led by WallachBeth Capital brought in new funding while aligning long-term investors — avoiding the heavy dilution that often plagues small-cap companies.
With AI adoption accelerating worldwide and hospitals demanding secure, intelligent solutions, HCTI’s timing is impeccable.
HCTI drives advancements in healthcare through innovative technology and deep industry expertise. The company partners with hospitals, health systems, payers, and pharma/life sciences organizations to enhance patient outcomes by optimizing their use of data and information technology.
They have earned HITRUST Certification for their Cloud and Data Platform (CaDP), known in the market as CloudEz™ and DataEz™. Achieving HITRUST Risk-based, 2-year (r2) Certified status underscores the company’s commitment to maintaining the highest standards of data protection and information security.
By empowering healthcare enterprises to adopt modern technologies, gain data-driven insights, and stay agile in an evolving market, Healthcare Triangle helps them respond effectively to business challenges and competitive pressures. Operating within highly regulated healthcare and life sciences environments, the company provides trusted expertise in digital transformation, covering cloud enablement, security and compliance, data lifecycle management, healthcare interoperability, and clinical and operational performance optimization.
Timing Is Everything
What makes HCTI especially interesting right now is its instinct for timing. The market is overflowing with AI hype, yet very few companies can translate the noise into tangible results. HCTI can. Its technology isn’t theoretical; it’s built on HITRUST-certified cloud and data platforms that already serve healthcare and life sciences clients where compliance is non-negotiable. It has the infrastructure, credentials, and customers — and now, with the pending Teyame deal, it may have the ignition spark it needed.
A Layer of Intelligence
Teyame’s platform integrates seamlessly with HCTI’s architecture, acting as an intelligent layer that transforms static data into live, dynamic dialogue. It doesn’t just secure compliance — it makes it conversational. For hospitals and health systems drowning in untapped information, this combination could finally make their data speak. HCTI isn’t just managing digital transformation; it’s humanizing it. That distinction is what separates a routine service provider from a true market-maker.
Execution Over Excuses
Of course, words are easy. What makes HCTI stand out is that it executes. The company didn’t merely announce its AI ambitions — it followed through by rebalancing its finances to support sustainable growth. It’s running a strategy that merges imagination with discipline, innovation with accountability. Investors have noticed: the stock has climbed over 30% in five weeks, not on hype but on visible traction and renewed confidence.
Small but Significant
It’s easy to overlook companies of HCTI’s size. The market often equates scale with value. History, however, tells a different story — the innovators who reshape industries often start small and punch above their weight. HCTI feels like it’s entering that early, formative phase — when potential turns into presence. The numbers may still be modest, but the ambition is unmistakably large.
Leading With Proof, Not Promises
HCTI’s leadership understands that while perception can move prices, only proof sustains them. With its AI acquisition strategy, strengthened capital position, and disciplined cost management, the company has achieved a rare trifecta for a microcap: relevance, control, and credibility. Those qualities don’t show up directly on financial statements — but they’re exactly what institutional investors look for when the smallcap market heats up again.
The New Narrative: Evidence Over Echo
The shift in this market cycle is clear — proof has replaced promise as the ultimate currency. The winners won’t be the loudest or the largest; they’ll be the ones who can verify results. After years as a behind-the-scenes healthcare IT provider focused on cloud compliance and security, HCTI is proving that those same foundations can power a next-generation AI engine for engagement and growth.
Healthcare Triangle Subsidiary QuantumNexis Reports $20M in Consumption-Based Revenue Processed on Ezovion Platform, Forecasts $37M Amid Rapid Growth
PLEASANTON, Calif., Oct. 1, 2025 /PRNewswire/ — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the “Company”), a leader in digital transformation solutions for healthcare and life sciences, today announced a significant milestone for its wholly-owned subsidiary, QuantumNexis.
QuantumNexis’s Ezovion Electronic Medical Record (EMR) platform has processed over $20 million in revenue generated by healthcare providers who rely on the platform to digitize and manage their operations. This milestone underscores Ezovion’s expanding role as the digital infrastructure powering hospitals, clinics, and specialty care providers across multiple markets, enabling seamless digitization, streamlined workflows, and improved patient outcomes.
As QuantumNexis accelerates its global expansion into India, Bangladesh, Saudi Arabia, and Malaysia, the total revenue processed through the platform by end users is projected to surge from $20 million to $37 million over the next six months. This growth reflects both rapid adoption by new customers and deeper engagement by existing healthcare providers who are expanding their digital footprints.
Suresh Venkatachari, Chairman of QuantumNexis, said, “Crossing $20 million in end-user revenue shows the trust providers place in Ezovion. With global expansion, we expect this to reach $37 million in six months. Our upcoming payment gateway will let QuantumNexis directly monetize this growth through recurring revenue.”
The Ezovion platform operates on a consumption-based model, scaling alongside its customers as they expand their digital healthcare ecosystems. This approach fosters predictable demand, deeper engagement, and long-term relationships, while setting the stage for future monetization.
Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle Inc, added,
“As customer consumption grows, so does QuantumNexis. The payment gateway enhances this model, unlocking high-volume recurring revenue and positioning HCTI for global scale and long-term value.”
Strategic Revenue Transformation: Integrated Payment Gateway Launch
QuantumNexis will soon launch its proprietary integrated payment gateway, representing a pivotal evolution in the company’s business model. The gateway will enable QuantumNexis to earn 0.05% five basis points) of all revenue processed through the platform, creating a direct, scalable revenue stream from the substantial transaction volume flowing through Ezovion.
Kasi Shanmugam, Head of Technology at QuantumNexis, stated,”Our gateway has been engineered with advanced security and scalability, seamlessly integrating clinical and financial workflows. This will support rapid, secure adoption as we expand globally.”
By embedding payment processing directly into clinical workflows, QuantumNexis eliminates friction for healthcare providers while capturing recurring transaction-based revenue that scales automatically with platform growth.
Strategic Impact for Shareholders
The QuantumNexis milestone and payment gateway launch create multiple value growth drivers for HCTI:
- $20M+ in end-user revenue already processed through the Ezovion platform, demonstrating strong market traction and platform adoption.
- Projected growth to $37M in end-user revenue within six months, driven by aggressive international expansion and deeping customer engagement with existing customers.
- Launch of an integrated payment gateway to directly monetize transaction flows, transforming platform activity into predictable recurring revenue for HCTI.
- Strategic positioning as a hybrid SaaS + fintech company, creating a differentiated investment thesis that appeals to both healthcare technology and fintech-focused institutional investors.
- Initial payment gateway deployments planned for late 2025, with comprehensive global scaling throughout 2026.
David Ayanoglou, Chief Financial Officer of Healthcare Triangle Inc, concluded,
“The rapid increase in end-user revenue processed through Ezovion reflects strong adoption and engagement by healthcare providers. By launching our payment gateway, HCTI can transform this activity into direct, recurring revenue while driving margin expansion and delivering long-term shareholder value.”
NEWS
Healthcare Triangle’s Strategic Intent Rewarded with a 32% Share Gain Since September (NASDAQ:HCTI)
Oct 14, 2025
Healthcare Triangle Plays Offense to Redefine What Aggressive Growth Looks Like (NASDAQ: HCTI)
Oct 13, 2025
Oct 10, 2025
Healthcare Triangle, a $16M Microcap, Targets Teyame.AI and Its $34M FY2025 (NASDAQ: HCTI)
Oct 10, 2025
Oct 9, 2025
Oct 8, 2025
Oct 8, 2025
Oct 8, 2025
Oct 3, 2025
Oct 3, 2025
Oct 2, 2025
Oct 2, 2025
Oct 2, 2025
Oct 2, 2025
Oct 1, 2025
Aug 4, 2025
Aug 1, 2025
Jul 31, 2025
Healthcare Triangle, Inc. Announces 1-for-249 Reverse Stock Split as Part of Nasdaq Compliance Plan
Jul 29, 2025
MANAGEMENT
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY HCTI AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.